Month: August 2021

Company annoucement – No. 50 / 2021 Interim report for H1 2021 Zealand Pharma Launches ZEGALOGUE® (dasiglucagon) Injection and Advances Pipeline Programs Across Multiple Therapeutic Areas Copenhagen, DK and Boston, MA, U.S. August 12, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078) a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced financial results for the first half of 2021. Financial results for the first half of 2021Revenue: DKK 132.1 million / USD 21.1 million (DKK 233.4 million / USD 35.1 million in the first six months of 2020). Net operating expenses: DKK -616.6 million / USD -98.5 million (DKK -437.2 million / USD -65.7 million in the first six months of 2020). Net operating result: DKK -550.8 million / USD -88.0 million...

Oslo, Norway – 12 August 2021 – IDEX Biometrics ASA, a leading provider of advanced fingerprint identification and authentication solutions, has prepared an updated Company Presentation for the first half year of 2021. The presentation is webcasted today at 15:00 CET, at: https://channel.royalcast.com/landingpage/hegnarmedia/20210812_2/ . The presentation slide deck is attached, as a PDF file, at the end of this release. The webcast and presentation slide deck will also be available as soon as practical at: https://www.idexbiometrics.com/investors/events-presentations/ For further information contact: Marianne Bøe, Investor Relations E-mail: marianne.boe@idexbiometrics.com Tel: +47 918 00186 About IDEX Biometrics IDEX Biometrics ASA (OSE: IDEX and Nasdaq: IDBA) is a leading provider of fingerprint identification technologies offering...

SAN RAMON, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) — CooperCompanies (NYSE: COO), today announced that the Chinese National Medical Products Administration (NMPA), which regulates medical devices and pharmaceuticals in China, has approved CooperVision MiSight® 1 day contact lenses for use within the country following a priority review. “We are extremely excited to receive this approval,” said Al White, President and CEO. “The increasing incidence of myopia is one of the most pressing global eye-health issues we face today, and receiving approval from the NMPA allows us to work closely with eye-care professionals proactively treating children in China. MiSight® is the most innovative contact lens in the market, and we remain incredibly passionate about promoting it along with our ortho-k and SightGlass Vision® myopia management products.” MiSight®...

Signs First Oklahoma Provider and Continued Execution of Carrier Agreements MIAMI, Aug. 12, 2021 (GLOBE NEWSWIRE) — Novus Acquisition and Development, Corp. (OTC Markets: NDEV), through its wholly-owned subsidiary WCIG Insurance Services, LLC., is a hybrid health insurance entity and, the nation’s first health carrier offering cannabis in health plans to recreational and medicinal users, today reported its second quarter financial results for the three months ended June 30, 2021 and its expansion into the Oklahoma market.    Novus continues to gather more health carriers and third-party administrators to add its cannabis benefits as a rider and/or as a supplement bundle to consumer health plans. These alliances realize the potential of increasing revenue and market share as consumer spending surges within the legal market. According...

VICTORIA, British Columbia, Aug. 12, 2021 (GLOBE NEWSWIRE) — CE Brands Inc. (TSXV: CEBI; CEBI.WT) (“CE Brands“),a data-driven consumer-electronics company, and its wholly-owned subsidiary eBuyNow eCommerce Ltd. (“eBuyNow“), are pleased to announce 4 new distribution and retail agreements, in line with the goal to become leaders in manufacturing, brand licensing, and global product distribution. The retail and distribution agreements cover India, Japan, Central Europe and Eastern Europe:A direct vendor relationship between eBuyNow and The Flipkart Group, one of India’s leading digital commerce entities and includes group companies Flipkart, Myntra, and PhonePe. Started in 2007, Flipkart has enabled millions of consumers, sellers, merchants, and small businesses to be a part of India’s e-commerce...

WAKEFIELD, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) — Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provided additional information regarding the status of its randomized, double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for the treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897). The Company is developing Brilacidin for treatment of COVID-19 under U.S. FDA Fast Track designation. Full enrollment in the 120-patient clinical trial was completed in early June 2021. The last patient follow-up visit occurred on July 30, 2021. The subject database remains blinded with the current emphasis on confirmation of all data entered at study sites, as well as completion of source data verification and the necessary checks and reviews...

SUWON, Republic of Korea, Aug. 12, 2021 (GLOBE NEWSWIRE) — OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for OLX104C, an investigational therapeutic for the treatment of androgenic alopecia, also known as male pattern baldness. Balding scalps are often associated with increased expression of the androgen receptor gene. The patent covers OliX’s proprietary technology, which reduces the expression of the androgen receptor and suppresses the hair loss process. Male pattern baldness is a disease of genetic disposition and affects an estimated 50 million men in the United States and more than 50 percent of men over age 50.i It is thought that the enzyme 5-alpha reductase...

IMAC reports 36% increase in revenues and 70% increase in patient visits as it invests in value-generating assets BRENTWOOD, Tenn., Aug. 12, 2021 (GLOBE NEWSWIRE) — IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or the “Company”), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announces financial results for the second quarter ended June 30, 2021. Financial Highlights from 2Q 2021 (all comparisons are for the quarter ended June 30, 2020, unless otherwise indicated):Total revenue was $3.4 million, compared with $2.5 million, an increase of 36% Patient visits were up 70% with more than 44,778 visits at IMAC Centers, compared to 26,335 Net loss was $2.5 million or $0.08 per share, compared with a net loss of $1.9 million...

SUNNYVALE, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) — NextNav, a leader in next generation GPS, announced today the release of its Unreal Engine plug-in, integrating its vertical positioning service, Pinnacle. Now, developers can unlock the power of 3D geolocation and z-axis across all games and applications built with the Unreal Engine. The launch of the plug-in comes just weeks after the company received an Epic MegaGrant, which it will use to bring its vertical location capabilities to the Unreal Engine. The plug-in delivers precise altitude data, allowing developers to integrate vertical location into any geolocation application built with the Unreal Engine, Epic Games’ real-time 3D tool for creating cutting-edge content and immersive experiences. Armed with the plug-in, developers can bring “floor-level” vertical location accuracy...

MONTRÉAL, Aug. 12, 2021 (GLOBE NEWSWIRE) — Bombardier Inc. (“Bombardier”) today announced that it has successfully closed its previously announced offering of US$750,000,000 aggregate principal amount of Senior Notes due 2028 (the “New Notes”). The New Notes carry a coupon of 6.000% per annum, mature on February 15, 2028 and were sold at 100.000% of par. Bombardier intends to use the net proceeds of this offering of New Notes, together with cash on hand, for the repayment and/or retirement of outstanding debt, including to redeem all of its outstanding 6.000% Senior Notes due October 2022, of which there is $514 million aggregate principal amount outstanding on the date hereof, and all of its outstanding 6.125% Senior Notes due 2023, of which there is $534 million aggregate principal amount outstanding on the date hereof, for related...